Hosted on MSN1mon
Sonnet BioTherapeutics begins trial combining SON-1010, trabectedin
Patients with unresectable, metastatic liposarcoma or leiomyosarcoma are the focus of this open-label, single-arm expansion cohort. The combination therapy will be administered in standard 21-day ...
Leiomyosarcoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Promising Leiomyosarcoma Therapies such as Lurbinectedin, Doxorubicin, Unesbulin, Dacarbazine, Rucaparib, Nivolumab, ...